Skip to main content
AMRN
NASDAQ Life Sciences

Amarin Reports Strong Q4 & Full Year 2025 Results, Achieves Positive Cash Flow Ahead of Schedule

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$15.52
Mkt Cap
$322.79M
52W Low
$7.08
52W High
$20.9
Market data snapshot near publication time

Summary

Amarin Corporation announced its Q4 and full year 2025 financial results, showcasing a significant reduction in losses and achieving positive cash flow ahead of schedule, driven by strategic initiatives and cost optimization.


Key Events

  • Significant Loss Reduction

    Amarin narrowed its Q4 2025 operating loss by 88% to $(6.3) million and its net loss by 97% to $(1.2) million, compared to Q4 2024.

  • Achieved Positive Cash Flow

    The company returned to positive cash flow in Q4 2025, ahead of schedule, and anticipates generating positive cash flow for the full year 2026.

  • Strong Financial Position

    Amarin ended 2025 with $302.6 million in cash and investments and remained debt-free, reflecting an $8.4 million year-over-year increase in cash.

  • Strategic Progress

    The company maintained U.S. market leadership for VASCEPA and expanded its European presence for VAZKEPA through a long-term partnership agreement, alongside significant cost reductions from its global restructuring plan.


Analysis

Amarin Corporation's latest financial report details a significant turnaround in its financial performance for Q4 and full year 2025. The dramatic reduction in operating and net losses, coupled with achieving positive cash flow ahead of schedule, signals successful execution of strategic initiatives and cost optimization efforts. This improved financial health, supported by a strong cash position and no debt, provides a solid foundation for the company's continued commercialization efforts for VASCEPA and VAZKEPA. Investors should note the company's ability to improve profitability and cash generation despite a revenue decline, which was partially attributed to a strategic transition in European sales.

At the time of this filing, AMRN was trading at $15.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $322.8M. The 52-week trading range was $7.08 to $20.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMRN - Latest Insights

AMRN
Jun 04, 2026, 10:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $14.50
Real-time Price: $15.24 info
Change: +$0.740 (+5%) info
Market Cap: $319.731M info
AMRN
May 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.80
Real-time Price: $15.24 info
Change: -$0.560 (-4%) info
Market Cap: $319.731M info
AMRN
May 14, 2026, 9:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.78
Real-time Price: $15.24 info
Change: +$0.460 (+3%) info
Market Cap: $319.731M info
AMRN
Apr 29, 2026, 5:38 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $14.29
Real-time Price: $15.24 info
Change: +$0.950 (+7%) info
Market Cap: $319.731M info
AMRN
Apr 29, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.96
Real-time Price: $15.24 info
Change: +$1.28 (+9%) info
Market Cap: $319.731M info
AMRN
Apr 29, 2026, 7:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.96
Real-time Price: $15.24 info
Change: +$1.28 (+9%) info
Market Cap: $319.731M info
AMRN
Apr 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.96
Real-time Price: $15.24 info
Change: +$1.28 (+9%) info
Market Cap: $319.731M info
AMRN
Apr 10, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $14.48
Real-time Price: $15.24 info
Change: +$0.760 (+5%) info
Market Cap: $319.731M info
AMRN
Apr 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.40
Real-time Price: $15.24 info
Change: +$0.840 (+6%) info
Market Cap: $319.731M info
AMRN
Mar 30, 2026, 5:57 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $15.24 info
Change: +$1.29 (+9%) info
Market Cap: $319.731M info